A phase 1/2 study of IMT-009, an antibody targeting CD161, in patients with advanced solid tumors or lymphomas

In August 2021, LLS made an equity investment in Immunitas Therapeutics to support the "Phase 1 Clinical Development of IMT-009, an Antibody Targeting CD161, in Patients With Advanced Solid Tumors or Lymphomas."

Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer. Their discovery engine combines deep expertise in single-cell genomics with customized machine learning approaches to elucidate immune cell populations that are key actors in immuno-oncology. Immunitas complements this process with bespoke in-house therapeutic discovery rooted in antibody display and immunization. The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT.

IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and lymphomas and is in a Phase 1 clinical trial (NCT05565417).